Fabrice André

67PUBLICATIONS
569CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Gene expression (incl. microarray and other genome-wide approaches)Predictive and prognostic markersCancer diagnosis
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (67)

|Mar 09, 2026
VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast Cancer.

Sara A Hurvitz, Rachel M Layman, Giuseppe Curigliano

|Feb 03, 2026
Recurrent Resistance Mutations to Lirafugratinib Inform Treatment Sequencing in FGFR2-Driven Tumors.

Francesco Facchinetti, Antoine Hollebecque, Rémy Barbé

|Jan 08, 2026
DESTINY-Breast08: A Phase Ib Study of Trastuzumab Deruxtecan in Combination with Other Anticancer Therapies in Patients with HER2-Low Metastatic Breast Cancer.

Komal Jhaveri, Sherene Loi, Erika Hamilton

|Dec 10, 2025
Novae: a graph-based foundation model for spatial transcriptomics data.

Quentin Blampey, Hakim Benkirane, Nadège Bercovici

|Oct 21, 2025
Working conditions associated with return to work 2 years after breast cancer: insights from a cohort study.

Garazi Ruiz de Azua, Idlir Licaj, Sandrine Pinto

|Sep 10, 2025
Molecular analysis of lung adenocarcinomas from the SAFIR02-Lung cohort reveals new metastasis-associated copy-number alterations including frequent mutant-specific KRAS-allelic imbalance and identifies CDKN2A homozygous deletions as an independent biomarker of poor prognosis.

Abderaouf Hamza, Pierre Gestraud, Maryam Karimi

Pageof 12

Frequent Collaborators

13 joint publications

Barbara Pistilli

11 joint publications

Stefan Michiels

8 joint publications

Benjamin Besse

8 joint publications

Anne-Laure Martin